Literature DB >> 16418802

HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption.

Emmanouil Papasavvas1, Jay R Kostman, Brian Thiel, Maxwell Pistilli, Agnieszka Mackiewicz, Andrea Foulkes, Robert Gross, Kimberly A Jordan, Douglas F Nixon, Robert Grant, Jean-Francois Poulin, Joseph M McCune, Karam Mounzer, Luis J Montaner.   

Abstract

The impact of transient viral load blips on anti-HIV-1 immune responses and on HIV-1 rebound following treatment interruption (TI) is not known. Clinical and immunological parameters were measured during 40 weeks of antiretroviral therapy (ART) and following TI in an observational cohort of 16 chronically HIV-1-infected subjects with or without observed viral load blips during ART. During therapy, blips in seven subjects were associated with higher anti-HIV-1 (p24) CD4+ T cell lymphoproliferative responses (p = 0.04), without a significant difference in T cell activation or total anti-HIV-1 CD8+ T cell interferon-gamma (IFN-gamma) responses when compared to nine matched non-blippers. Therapy interruption resulted in a significantly higher viral rebound in blippers by 8 week despite retention of higher lymphoproliferative p24 responses (p = 0.01) and a rise in CD3+ T cell activation (p = 0.04) and anti-HIV-1 CD8+ T cell responses in blippers by week 4 when compared to non-blippers. Past week 4 of interruption, therapy re-initiation criteria were also met by a higher frequency in blippers by week 14 (p < 0.04) with no difference between groups by week 24. These data support that blippers have higher anti-HIV lymphoproliferative responses while on ART but experience equal to higher viral rebound as compared to matched non-blippers upon TI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16418802     DOI: 10.1007/s10875-006-7518-8

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  75 in total

1.  Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses.

Authors:  Franco Lori; Andrea Foli; Renato Maserati; Elena Seminari; Jianqing Xu; Lucia Whitman; Elisabetta Ravot; Francesco Alberici; Lucia Lopalco; Julianna Lisziewicz
Journal:  HIV Clin Trials       Date:  2002 Mar-Apr

2.  Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.

Authors:  M Clerici; E Seminari; F Suter; F Castelli; A Pan; M Biasin; F Colombo; D Trabattoni; F Maggiolo; G Carosi; R Maserati
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

3.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

4.  Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy.

Authors:  J P Casazza; M R Betts; L J Picker; R A Koup
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals.

Authors:  M Larsson; X Jin; B Ramratnam; G S Ogg; J Engelmayer; M A Demoitie; A J McMichael; W I Cox; R M Steinman; D Nixon; N Bhardwaj
Journal:  AIDS       Date:  1999-05-07       Impact factor: 4.177

6.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

7.  Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.

Authors:  J W Cohen Stuart; A M Wensing; C Kovacs; M Righart; D de Jong; S Kaye; R Schuurman; C J Visser; C A Boucher
Journal:  J Acquir Immune Defic Syndr       Date:  2001-10-01       Impact factor: 3.731

8.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection.

Authors:  M Matloubian; R J Concepcion; R Ahmed
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Combination antiretroviral therapy and recent declines in AIDS incidence and mortality.

Authors:  E Vittinghoff; S Scheer; P O'Malley; G Colfax; S D Holmberg; S P Buchbinder
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

10.  Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure.

Authors:  José A Mira; Juan Macías; Carmen Nogales; Javier Fernández-Rivera; José A García-García; Antonio Ramos; Juan A Pineda
Journal:  Antivir Ther       Date:  2002-12
View more
  10 in total

1.  Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Authors:  Emmanouil Papasavvas; Andrea Foulkes; Xiangfan Yin; Jocelin Joseph; Brian Ross; Livio Azzoni; Jay R Kostman; Karam Mounzer; Jane Shull; Luis J Montaner
Journal:  Immunology       Date:  2015-05-19       Impact factor: 7.397

2.  Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.

Authors:  Marta E Bull; Jennifer L McKernan; Sheila Styrchak; Kelli Kraft; Jane Hitti; Susan E Cohn; Kenneth Tapia; Wenjie Deng; Sarah Holte; James I Mullins; Robert W Coombs; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2019-04-30       Impact factor: 2.205

3.  Increased microbial translocation in ≤ 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Andrea Foulkes; Avy Violari; Mark F Cotton; Maxwell Pistilli; Griffin Reynolds; Xiangfan Yin; Deborah K Glencross; Wendy S Stevens; James A McIntyre; Luis J Montaner
Journal:  Pediatr Infect Dis J       Date:  2011-10       Impact factor: 2.129

4.  Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.

Authors:  Christie Joya; Seung Hyun Won; Christina Schofield; Tahaniyat Lalani; Ryan C Maves; Karl Kronmann; Robert Deiss; Jason Okulicz; Brian K Agan; Anuradha Ganesan
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

5.  HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.

Authors:  Brinda Emu; Elizabeth Sinclair; Hiroyu Hatano; April Ferre; Barbara Shacklett; Jeffrey N Martin; J M McCune; Steven G Deeks
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

6.  Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.

Authors:  Pedro Castro; Montserrat Plana; Raquel González; Anna López; Anna Vilella; Jose M Nicolas; Teresa Gallart; Tomàs Pumarola; José M Bayas; José M Gatell; Felipe García
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-16       Impact factor: 2.205

7.  Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Authors:  Emmanouil Papasavvas; Maxwell Pistilli; Griffin Reynolds; Robert Bucki; Livio Azzoni; Jihed Chehimi; Paul A Janmey; Mark J DiNubile; Joe Ondercin; Jay R Kostman; Karam C Mounzer; Luis J Montaner
Journal:  AIDS       Date:  2009-01-28       Impact factor: 4.177

8.  Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.

Authors:  Emmanouil Papasavvas; Steven M Lada; Jocelin Joseph; Xiangfan Yin; Qin Liu; Livio Azzoni; Karam Mounzer; Jay R Kostman; Douglas Richman; Luis J Montaner
Journal:  AIDS       Date:  2018-08-24       Impact factor: 4.177

9.  SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques.

Authors:  Haitao Hu; Lucio Gama; Pyone P Aye; Janice E Clements; Peter A Barry; Andrew A Lackner; Drew Weissman
Journal:  Retrovirology       Date:  2011-07-13       Impact factor: 4.602

10.  Do HIV-specific CTL continue to have an antiviral function during antiretroviral therapy? If not, why not, and what can be done about it?

Authors:  Dorian McIlroy
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.